MCID: CRV038
MIFTS: 56

Cervical Squamous Cell Carcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Cervical Squamous Cell Carcinoma

MalaCards integrated aliases for Cervical Squamous Cell Carcinoma:

Name: Cervical Squamous Cell Carcinoma 12 58 54 15 17 70
Squamous Cell Carcinoma of the Cervix Uteri 12 58
Squamous Cell Carcinoma of Cervix 12

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:3744
NCIt 50 C4028
SNOMED-CT 67 254886006
ICD10 via Orphanet 33 C53.0 C53.1 C53.8
UMLS via Orphanet 71 C0279671
Orphanet 58 ORPHA213767
UMLS 70 C0279671

Summaries for Cervical Squamous Cell Carcinoma

Disease Ontology : 12 A cervix carcinoma that has material basis in squamous cells of the cervix.

MalaCards based summary : Cervical Squamous Cell Carcinoma, also known as squamous cell carcinoma of the cervix uteri, is related to squamous cell carcinoma and cervical intraepithelial neoplasia. An important gene associated with Cervical Squamous Cell Carcinoma is LOC105379013 (Uncharacterized LOC105379013), and among its related pathways/superpathways are Pathways in cancer and DNA Damage. The drugs Epoetin alfa and Topotecan have been mentioned in the context of this disorder. Affiliated tissues include cervix, uterus and lymph node, and related phenotype is digestive/alimentary.

Related Diseases for Cervical Squamous Cell Carcinoma

Diseases related to Cervical Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 166)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 32.3 TP63 SERPINB3 MKI67 DAPK1 CDKN2A
2 cervical intraepithelial neoplasia 31.8 MKI67 KRT8 CDKN2A
3 cervical cancer 31.4 TYMP TP63 SERPINB3 RASSF1 MIR200A DAPK1
4 cervical adenocarcinoma 31.2 RASSF1 KRAS CDKN2A
5 papilloma 31.0 TP63 RASSF1 KRT8 KRAS CDKN2A
6 anal squamous cell carcinoma 30.7 RASSF1 MLH1 CDKN2A
7 adenoid cystic carcinoma 30.7 TP63 RASSF1 KRAS DAPK1 CDKN2A
8 basaloid squamous cell carcinoma 30.7 TP63 KRT8 CDKN2A
9 endometrial adenocarcinoma 30.6 MLH1 MIR200A KRAS CDKN2A
10 small cell carcinoma 30.5 KRT8 KRAS CDKN2A
11 adenosquamous carcinoma 30.4 TP63 KRT8 KRAS CDKN2A
12 transitional cell carcinoma 30.2 TP63 MLH1 MKI67 KRT8 DAPK1 CDKN2A
13 esophageal cancer 29.6 XIST TYMP RASSF1 MMP14 MLH1 MIR200A
14 bladder cancer 29.5 XIST TYMP TP63 RASSF1 MLH1 MKI67
15 microinvasive cervical squamous cell carcinoma 11.7
16 cervical verrucous carcinoma 11.2
17 cervical basaloid squamous cell carcinoma 11.2
18 cervical keratinizing squamous cell carcinoma 11.2
19 cervical lymphoepithelioma-like carcinoma 11.2
20 cervix uteri carcinoma in situ 10.8
21 suppressor of tumorigenicity 3 10.8
22 adenocarcinoma 10.6
23 squamous cell papilloma 10.5
24 spitz nevus 10.5 MKI67 CDKN2A
25 necrotizing sialometaplasia 10.5 TP63 MKI67
26 ameloblastic carcinoma 10.4 TP63 MKI67 CDKN2A
27 atypical polypoid adenomyoma 10.4 MLH1 CDKN2A
28 cervicitis 10.4
29 adenomyoma 10.4 MLH1 CDKN2A
30 benign breast phyllodes tumor 10.4 TP63 MKI67
31 cholecystitis 10.4 RASSF1 DAPK1 CDKN2A
32 oral leukoplakia 10.4 TP63 MKI67
33 intracranial meningioma 10.4 MLH1 MKI67 CDKN2A
34 chronic cervicitis 10.4
35 actinic keratosis 10.4 TP63 MMP14 CDKN2A
36 trachea carcinoma in situ 10.4 KRAS CDKN2A
37 melanoma in congenital melanocytic nevus 10.4 MMP14 MKI67 CDKN2A
38 breast papillomatosis 10.4 MMP14 CDKN2A
39 papillary thyroid microcarcinoma 10.4 TP63 MKI67
40 polymorphous low-grade adenocarcinoma 10.4 TP63 MKI67
41 chlamydia 10.4
42 pulmonary vein stenosis 10.4 TYMP MKI67
43 mucoepidermoid carcinoma 10.4 TP63 MKI67 CDKN2A
44 transverse colon cancer 10.4 MLH1 KRAS
45 malignant exocrine pancreas neoplasm 10.4 KRAS CDKN2A
46 ascending colon cancer 10.3 MLH1 KRAS
47 uterine corpus cancer 10.3 MLH1 KRAS CDKN2A
48 lung benign neoplasm 10.3 RASSF1 KRAS CDKN2A
49 mucinous adenocarcinoma 10.3 MLH1 KRAS CDKN2A
50 neurenteric cyst 10.3 KRT8 KRAS

Graphical network of the top 20 diseases related to Cervical Squamous Cell Carcinoma:



Diseases related to Cervical Squamous Cell Carcinoma

Symptoms & Phenotypes for Cervical Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Cervical Squamous Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.17 CDKN2A KRAS KRT8 MLH1 MMP14 RASSF1

Drugs & Therapeutics for Cervical Squamous Cell Carcinoma

Drugs for Cervical Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Epoetin alfa Phase 4 113427-24-0
2
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
3
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
4
Fluorouracil Approved Phase 3 51-21-8 3385
5
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
6
Vinblastine Approved Phase 3 865-21-4 241903 13342
7
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
8
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
9
Ifosfamide Approved Phase 3 3778-73-2 3690
10
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
11
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
13 topoisomerase I inhibitors Phase 3
14 Vitamin B9 Phase 3
15 Folic Acid Antagonists Phase 3
16 Folate Phase 3
17 Vitamin B Complex Phase 3
18 Antimetabolites Phase 3
19 Dermatologic Agents Phase 3
20 Antibiotics, Antitubercular Phase 3
21 Anti-Bacterial Agents Phase 3
22 Mitomycins Phase 3
23
Isophosphamide mustard Phase 3 100427
24 Antimitotic Agents Phase 3
25 Tubulin Modulators Phase 3
26
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
27
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
28
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
29
Amifostine Approved, Investigational Phase 1, Phase 2 20537-88-6 2141
30
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
31
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
32
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
33
carbamide peroxide Approved Phase 1, Phase 2 124-43-6
34
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
35
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
36
Lenograstim Approved, Investigational Phase 2 135968-09-1
37
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
38
Bevacizumab Approved, Investigational Phase 2 216974-75-3
39
Zinc Approved, Investigational Phase 2 7440-66-6 32051
40
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594
41
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
42
Indomethacin Approved, Investigational Phase 2 53-86-1 3715
43
Gemcitabine Approved Phase 2 95058-81-4 60750
44
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
45
Copper Approved, Investigational Phase 2 7440-50-8 27099
46
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 444795 5538
47 Bryostatin 1 Investigational Phase 2 83314-01-6
48
Tirapazamine Investigational Phase 2 27314-97-2
49
Exatecan Investigational Phase 2 171335-80-1
50
Cediranib Investigational Phase 2 288383-20-0 9933475

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin) Completed NCT00046969 Phase 4 cisplatin
2 Randomized Phase III Study Of Neoadjuvant Chemotherapy Followed By Surgery Vs. Concomitant Radiotherapy And Chemotherapy In FIGO Ib2, IIa>4 cm or IIb Cervical Cancer Unknown status NCT00039338 Phase 3 cisplatin
3 A Randomized Comparison of Radiation vs Radiation Plus Weekly Cisplatin vs Radiation Plus PVI (Protracted Venous Infusion) 5-FU in Patients With Stage II-B, III-B, and IV-A Carcinoma of the Cervix With Negative Paraaortic Nodes Completed NCT00003078 Phase 3 cisplatin;fluorouracil
4 A Randomized Phase III Study of Cisplatin Versus Cisplatin Plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
5 A Randomized Phase III Study of Chemotherapy and Radiotherapy Versus Radiotherapy Alone as Adjuvant Treatment to Patients With Node Positive Stages IB or IIA Cervix Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
6 Study of Two Fractions Versus Three Fractions High Dose Rate Brachytherapy in Locally Advanced Carcinoma of Uterine Cervix After Pelvic Concurrent Chemoradiotherapy - a Randomized Controlled Trial Completed NCT02765919 Phase 3
7 A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy Completed NCT01365156 Phase 3
8 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
9 Treatment of Patients With Stage IB2 Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Tailored Chemo-Radiation Versus Primary Chemo-Radiation Terminated NCT00054067 Phase 3 cisplatin
10 An International Multi Center Phase III Study of Chemoradiotherapy Versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
11 Feasibility Study of the Combination of Radiotherapy, Chemotherapy and Hyperthermia for the Treatment of Stage IIB-III-IVA Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
12 Phase II Study of Weekly Neoadjuvant Chemotherapy Followed by Radical Chemoradiation for Locally Advanced Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
13 A Two-Stage Multicenter Phase II Trial of Concurrent Panitumumab Immunotherapy, Cisplatin Chemotherapy and Pelvic Radiotherapy for Primary Cancer of the Uterine Cervix Stage IB-IIIB Unknown status NCT01158248 Phase 2 cisplatin
14 Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer (SIDE, Advanced Squamous Cervical Cancer Trial) Unknown status NCT02879214 Phase 2
15 A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix Completed NCT00087126 Phase 2 topotecan hydrochloride
16 A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231517, IND #40061) In the Treatment Of Recurrent Carcinoma Of The Cervix Completed NCT00087113 Phase 2 pemetrexed disodium
17 A Limited Access Phase II Trial Of Capecitabine In Advanced, Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00016926 Phase 2 capecitabine
18 A Two Part Phase I/II Study Of Extended Field External Irradiation And Intracavitary Brachytherapy Combined With Chemotherapy And Amifostine In Carcinoma Of The Cervix With Positive Para-Aortic Or High Common Iliac Lymph Nodes Completed NCT00012012 Phase 1, Phase 2 Amifostine trihydrate;Cisplatin
19 Phase II Clinical Trial of Bryostatin-1, NSC 339555, and Cisplatin in Patients With Recurrent and/or Advanced Inoperable Squamous Cell, Adeno or Adenosquamous Cell Carcinoma of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
20 Phase II Evaluation of Oxaliplatin in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix Completed NCT00005837 Phase 2 oxaliplatin
21 A Phase I/II Study Of Whole Pelvic Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis Completed NCT00003379 Phase 1, Phase 2 cisplatin;paclitaxel
22 Evaluation of Intravenously Administered Tirapazamine Plus Cisplatin in Cervical Cancer Completed NCT00003369 Phase 2 cisplatin;tirapazamine
23 Phase II Clinical Trial of Interleukin-12 in Patients With Advanced, Recurrent or Inoperable Carcinoma of the Cervix Completed NCT00003017 Phase 2
24 ALPHA INTERFERON AND CIS-RETINOIC ACID FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMAS Completed NCT00002506 Phase 2 isotretinoin
25 A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis ± Chemotherapy for Post-Operative Patients With Either Endometrial or Cervical Carcinoma Completed NCT00331760 Phase 2 cisplatin
26 A Pilot Study of MR-Guided High Dose Rate Brachytherapy With MR Image Acquisition for Patients With Cervical Cancer Completed NCT00278304 Phase 2
27 A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix Completed NCT00276796 Phase 2 cisplatin;paclitaxel;topotecan hydrochloride
28 A Limited Access Phase II Trial of Cetuximab (C225, NSC #714692) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix Completed NCT00101192 Phase 2 cisplatin
29 A Phase II Evaluation of SU5416 (NSC 696819) in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix Completed NCT00026260 Phase 2 semaxanib
30 A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Advanced or Recurrent Squamous Cell Cancer of the Cervix Completed NCT00004866 Phase 2 exatecan mesylate
31 A Phase I/II, Multi-Center Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer Completed NCT01230996 Phase 1, Phase 2 Cisplatin
32 CIRCCa - A Randomized Double Blind Phase II Trial of Carboplatin-Paclitaxel Plus Cediranib Versus Carboplatin-Paclitaxel Plus Placebo in Metastatic/Recurrent Cervical Cancer Completed NCT01229930 Phase 2 carboplatin;cediranib maleate;paclitaxel
33 A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer Completed NCT00023660 Phase 1, Phase 2 celecoxib;cisplatin;fluorouracil
34 A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma Completed NCT00005999 Phase 2 arsenic trioxide
35 A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma Completed NCT00005070 Phase 2 irofulven
36 Phase II Investigation of Topotecan and Taxol in Patients With Recurrent/Metastatic Cancer of the Cervix Completed NCT00003065 Phase 2 paclitaxel;topotecan hydrochloride
37 Neoadjuvant Chemotherapy With Docetaxel in Advanced Cervical Carcinoma Completed NCT00003445 Phase 2 docetaxel
38 A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins Completed NCT00002916 Phase 2
39 A LIMITED ACCESS PHASE II TRIAL OF CISPLATIN AND NAVELBINE (VINORELBINE) IN ADVANCED AND RECURRENT SQUAMOUS CELL CARCINOMA OF THE CERVIX Completed NCT00002813 Phase 2 cisplatin;vinorelbine tartrate
40 Phase I/II Study of Carboplatin in Association With Weekly Oral Topotecan in Patients With Metastatic or Recurrent Cervical Cancer Completed NCT00807079 Phase 1, Phase 2 carboplatin;topotecan hydrochloride
41 Feasibility Study of Safety, Toxicity, and Compliance of Concomitant Chemoradiotherapy for HIV-Associated Locally-Advanced Cervical Cancer Completed NCT01590017 Phase 2 cisplatin
42 A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix Completed NCT00691301 Phase 2 cisplatin;pemetrexed disodium
43 Phase II Randomized Assessing Pelvic Irradiation Combined With Cisplatin Alone or Cisplatin Plus Cetuximab in Patients With Carcinoma of the Cervix Stage IB2, II and III Completed NCT00957411 Phase 2 cisplatin
44 A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00031993 Phase 2 erlotinib hydrochloride
45 A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00041093 Phase 2 Docetaxel
46 A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Completed NCT00499031 Phase 2
47 A Phase II Trial of Bevacizumab (rhuMAB VEGF) (NSC #704865) in the Treatment of Persistent and Recurrent Squamous Cell Carcinoma of the Cervix (Group A) Completed NCT00025233 Phase 2
48 A Simplified Approach of Complete Nerve-sparing Type C1 Radical Hysterectomy for Cervical Cancer, a Phase II Study Completed NCT02562729 Phase 2
49 IMMUNOCERV: Evaluating the Safety of Chemoradiation Combined With PDS0101 Immunotherapy in Treating Locally Advanced Cervical Cancer Recruiting NCT04580771 Phase 2 Cisplatin
50 A Two-Cohort Randomized Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3) Recruiting NCT03267680 Phase 2 Cyclophosphamide;Indomethacin;Omeprazole

Search NIH Clinical Center for Cervical Squamous Cell Carcinoma

Genetic Tests for Cervical Squamous Cell Carcinoma

Anatomical Context for Cervical Squamous Cell Carcinoma

MalaCards organs/tissues related to Cervical Squamous Cell Carcinoma:

40
Cervix, Uterus, Lymph Node, Skin, Ovary, Endothelial, Spleen

Publications for Cervical Squamous Cell Carcinoma

Articles related to Cervical Squamous Cell Carcinoma:

(show top 50) (show all 1336)
# Title Authors PMID Year
1
Usefulness of p16 for differentiating primary pulmonary squamous cell carcinoma from cervical squamous cell carcinoma metastatic to the lung. 54 61
19369633 2009
2
Methylation of the RASSF1A gene promoter in Uigur women with cervical squamous cell carcinoma. 54 61
19366060 2009
3
[Expression of Skp2 in cervical squamous cell carcinoma and precancerous lesions and its correlation with HPV16/18 infection]. 61 54
19094580 2008
4
Coordinate expression of cytokeratin 8 and cytokeratin 17 immunohistochemical staining in cervical intraepithelial neoplasia and cervical squamous cell carcinoma: an immunohistochemical analysis and review of the literature. 54 61
18191996 2008
5
Relationship between decreased expression of squamous cell carcinoma antigen 2 and E-cadherin in primary cervical cancer lesions and lymph node metastasis. 54 61
18097581 2008
6
Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. 61 54
17467893 2007
7
Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. 61 54
17306351 2007
8
Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. 54 61
16818688 2006
9
Reverse transcription-polymerase chain reaction and western blotting analysis for detection of p63 isoforms in uterine cervical cancers. 54 61
16884378 2006
10
EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. 54 61
16425263 2006
11
Expression of thymidine phosphorylase as an effect prediction factor for uterine cervical squamous cell carcinoma after radiotherapy: an immunohistochemical study. 54 61
16803522 2006
12
[Expression of key cell cycle markers in squamous cell carcinoma of the cervix positive in human papillomavirus: a comparative study between Chinese and Australian populations]. 61 54
16677523 2006
13
Radiation-induced cell death is independent of the apoptotic signals mediated by death-associated protein kinase in human cervical squamous cell carcinoma cells. 54 61
16142356 2005
14
Reduced radiosensitivity and increased CD40 expression in cyclophosphamide-resistant subclones established from human cervical squamous cell carcinoma cells. 61 54
16142355 2005
15
Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. 61 54
15843547 2005
16
Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma. 61 54
14614573 2004
17
P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. 61 54
14599865 2003
18
Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy. 54 61
12909236 2003
19
Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis. 61 54
11876385 2002
20
Expression of topoisomerase II and Ki-67 in cervical carcinoma--clinicopathological study using immunohistochemistry. 61 54
10752690 2000
21
Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis. 61 54
10810442 2000
22
Thymidine phosphorylase expression in tumor stroma of uterine cervical carcinomas: histological features and microvessel density. 54 61
10695991 2000
23
Immunohistochemical and DNA sequencing analysis on human mismatch repair gene MLH1 in cervical squamous cell carcinoma with LOH of this gene. 54 61
10769651 2000
24
Biological implications of growth factors on the mechanism of invasion in gynecological tumor cells. 61 54
10545752 1999
25
Intensity-modulated radiotherapy combined with intracavitary brachytherapy for locally advanced cervical cancer with uterus didelphys. 61
33718560 2021
26
Hormone replacement therapy and cervical cancer: a systematic review of the literature. 61
33236658 2021
27
Would Women With Solid Organ Transplant Qualify for Triennial Cervical Cancer Screening as Recommended by the American College of Obstetricians and Gynecologists in 2016 and American Society for Colposcopy and Cervical Pathology in 2019? 61
33631778 2021
28
COVID‑19 and SARS‑CoV‑2 host cell entry mediators: Expression profiling of TMRSS4 in health and disease. 61
33649798 2021
29
Rapid identification of cervical adenocarcinoma and cervical squamous cell carcinoma tissue based on Raman spectroscopy combined with multiple machine learning algorithms. 61
33212265 2021
30
Discovery and validation of novel biomarkers for detection of cervical cancer. 61
33624385 2021
31
Cervical HSIL Involving the Endometrium and Adenomyosis: A Case Report and Literature Review. 61
33775028 2021
32
Identification of an immune-based mRNA-lncRNA signature for overall survival in cervical squamous cell carcinoma. 61
33724869 2021
33
Demonstrating the effect of SHP2 inhibitor on cervical squamous cell carcinoma from the perspective of ZAP70. 61
33661186 2021
34
Retraction: LncRNA SRA1 is downregulated in HPV-negative cervical squamous cell carcinoma (CSCC) and regulates cancer cell behaviors. 61
33521813 2021
35
Pathologic Determination of Multifocality in pT1a1 Squamous Cell Carcinoma of the Cervix: A Retrospective Analysis. 61
33616457 2021
36
Comparative study on the oncological prognosis of laparoscopy and laparotomy for stage IIA1 cervical squamous cell carcinoma. 61
32859433 2021
37
Detection of DKK-1 gene methylation in exfoliated cells of cervical squamous cell carcinoma and its relationship with high risk HPV infection. 61
33547934 2021
38
Expressions of m6A RNA methylation regulators and their clinical predictive value in cervical squamous cell carcinoma and endometrial adenocarcinoma. 61
33006785 2021
39
A novel prognostic prediction model based on seven immune-related RNAs for predicting overall survival of patients in early cervical squamous cell carcinoma. 61
33588862 2021
40
Exosome-derived miR-142-5p remodels lymphatic vessels and induces IDO to promote immune privilege in the tumour microenvironment. 61
32929219 2021
41
Predictive Ki-67 Proliferation Index of Cervical Squamous Cell Carcinoma Based on IVIM-DWI Combined with Texture Features. 61
33531882 2021
42
Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker. 61
33679809 2021
43
Cervical Superficially Invasive Squamous Cell Carcinoma With Supraclavicular Lymph Node Metastasis: A Case Report. 61
32897965 2021
44
Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma. 61
33748188 2021
45
Effect of pre-operative radiotherapy on long-term outcomes among women with Stage IB1 to IIB cervical squamous cell carcinoma. 61
33141931 2021
46
Periostin+ cancer-associated fibroblasts promote lymph node metastasis by impairing the lymphatic endothelial barriers in cervical squamous cell carcinoma. 61
33124726 2021
47
Raman spectroscopic study of cervical precancerous lesions and cervical cancer. 61
33404885 2021
48
Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer. 61
33303568 2021
49
A novel lymphatic pattern promotes metastasis of cervical cancer in a hypoxic tumour-associated macrophage-dependent manner. 61
33484377 2021
50
Clinicopathologic features and outcome of cervical cancer: implications for treatment. 61
33577024 2021

Variations for Cervical Squamous Cell Carcinoma

Cosmic variations for Cervical Squamous Cell Carcinoma:

9 (show top 50) (show all 907)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM123189243 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.270G>A p.L90= 8:116848969-116848969 9
2 COSM127848324 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.127G>A p.E43K 8:116848969-116848969 9
3 COSM123189233 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.249G>A p.L83= 8:116848948-116848948 9
4 COSM127848316 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.106G>A p.E36K 8:116848948-116848948 9
5 COSM101184918 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4630C>G p.L1544V 16:2086857-2086857 9
6 COSM90408532 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4906C>G p.L1636V 16:2086857-2086857 9
7 COSM149806850 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4843C>G p.L1615V 16:2086857-2086857 9
8 COSM87033167 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4975C>G p.L1659V 16:2086857-2086857 9
9 COSM151515645 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4900C>G p.L1634V 16:2086857-2086857 9
10 COSM150318236 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4774C>G p.L1592V 16:2086857-2086857 9
11 COSM102623419 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4774C>G p.L1592V 16:2086857-2086857 9
12 COSM151373080 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4969C>G p.L1657V 16:2086857-2086857 9
13 COSM150359241 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4771C>G p.L1591V 16:2086857-2086857 9
14 COSM151750121 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4846C>G p.L1616V 16:2086857-2086857 9
15 COSM110108009 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4666C>G p.L1556V 16:2086857-2086857 9
16 COSM148986154 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4777C>G p.L1593V 16:2086857-2086857 9
17 COSM136621744 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4807C>G p.L1603V 16:2086857-2086857 9
18 COSM150579385 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4768C>G p.L1590V 16:2086857-2086857 9
19 COSM147699343 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4846C>G p.L1616V 16:2086857-2086857 9
20 COSM122748443 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.434G>T p.C145F 17:7673790-7673790 9
21 COSM93517877 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.868C>A p.R290S 17:7673752-7673752 9
22 COSM144129341 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.242G>T p.S81I 17:7674244-7674244 9
23 COSM143944858 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.109C>T p.R37* 17:7674945-7674945 9
24 COSM144310445 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.700C>T p.R234C 17:7673803-7673803 9
25 COSM121892294 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.434G>T p.C145F 17:7673790-7673790 9
26 COSM143371865 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.469C>T p.R157* 17:7674945-7674945 9
27 COSM145017326 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.407G>A p.R136H 17:7675088-7675088 9
28 COSM143156696 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.224A>G p.Y75C 17:7674262-7674262 9
29 COSM143157606 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.109C>T p.R37* 17:7674945-7674945 9
30 COSM142566486 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.701G>C p.R234P 17:7673802-7673802 9
31 COSM122734408 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.421C>T p.R141C 17:7673803-7673803 9
32 COSM121883974 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.422G>C p.R141P 17:7673802-7673802 9
33 COSM144086975 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.47G>A p.R16H 17:7675088-7675088 9
34 COSM144653059 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.310G>A p.V104M 17:7675185-7675185 9
35 COSM88036027 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 17:7674188-7674188 9
36 COSM145017959 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.700C>T p.R234C 17:7673803-7673803 9
37 COSM143943866 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.59A>G p.H20R 17:7675076-7675076 9
38 COSM143168691 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.353G>T p.C118F 17:7673790-7673790 9
39 COSM121894970 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.452G>A p.R151H 17:7673772-7673772 9
40 COSM142846443 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.550G>A p.D184N 17:7675062-7675062 9
41 COSM121875983 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.347G>A p.R116Q 17:7674220-7674220 9
42 COSM143370595 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.407G>A p.R136H 17:7675088-7675088 9
43 COSM143370869 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 9
44 COSM106069893 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.848G>A p.R283H 17:7673772-7673772 9
45 COSM145017657 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 9
46 COSM112308199 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.719G>T p.S240I 17:7674244-7674244 9
47 COSM143376130 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.329G>C p.S110T 17:7673814-7673814 9
48 COSM143422228 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.602G>T p.S201I 17:7674244-7674244 9
49 COSM143384418 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.433G>A p.D145N 17:7675062-7675062 9
50 COSM144024948 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.517G>A p.D173N 17:7675062-7675062 9

Copy number variations for Cervical Squamous Cell Carcinoma from CNVD:

7 (show all 38)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 191444 5 1 15100000 Gain PDCD6 Cervical squamous cell carcinoma
2 191466 5 1 18500000 Gain TENT4A Cervical squamous cell carcinoma
3 191467 5 1 18500000 Gain SDHA Cervical squamous cell carcinoma
4 191468 5 1 18500000 Gain SRD5A1 Cervical squamous cell carcinoma
5 191624 5 1 42400000 Gain RPL37 Cervical squamous cell carcinoma
6 191625 5 1 42400000 Gain SKP2 Cervical squamous cell carcinoma
7 191627 5 1 42400000 Gain SLC1A3 Cervical squamous cell carcinoma
8 191642 5 1 4400000 Gain IRX2 Cervical squamous cell carcinoma
9 191643 5 1 4400000 Gain NDUFS6 Cervical squamous cell carcinoma
10 191644 5 1 4400000 Gain TERT Cervical squamous cell carcinoma
11 191646 5 1 4400000 Gain TRIP13 Cervical squamous cell carcinoma
12 191726 5 1 8200000 Gain IRX4 Cervical squamous cell carcinoma
13 195451 5 15100000 18500000 Gain ANKH Cervical squamous cell carcinoma
14 195452 5 15100000 18500000 Gain ZNF622 Cervical squamous cell carcinoma
15 195453 5 15100000 23300000 Gain MYO10 Cervical squamous cell carcinoma
16 195454 5 15100000 29300000 Gain BASP1 Cervical squamous cell carcinoma
17 198725 5 29300000 34400000 Gain DROSHA Cervical squamous cell carcinoma
18 198726 5 29300000 34400000 Gain GOLPH3 Cervical squamous cell carcinoma
19 198727 5 29300000 34400000 Gain MTMR12 Cervical squamous cell carcinoma
20 198728 5 29300000 34400000 Gain SUB1 Cervical squamous cell carcinoma
21 199076 5 34400000 38500000 Gain DNAJC21 Cervical squamous cell carcinoma
22 199078 5 34400000 38500000 Gain LMBRD2 Cervical squamous cell carcinoma
23 199079 5 34400000 38500000 Gain NIPBL Cervical squamous cell carcinoma
24 199080 5 34400000 38500000 Gain RAD1 Cervical squamous cell carcinoma
25 199082 5 34400000 38500000 Gain TARS1 Cervical squamous cell carcinoma
26 199083 5 34400000 38500000 Gain WDR70 Cervical squamous cell carcinoma
27 199384 5 38500000 42400000 Gain NUP155 Cervical squamous cell carcinoma
28 199385 5 38500000 42400000 Gain OXCT1 Cervical squamous cell carcinoma
29 199684 5 42400000 45800000 Gain CCL28 Cervical squamous cell carcinoma
30 199685 5 42400000 45800000 Gain FBXO4 Cervical squamous cell carcinoma
31 199686 5 42400000 45800000 Gain PAIP1 Cervical squamous cell carcinoma
32 199689 5 42400000 47700000 Gain ZNF131 Cervical squamous cell carcinoma
33 199835 5 4400000 6000000 Gain ICE1 Cervical squamous cell carcinoma
34 202451 5 8200000 15100000 Gain CCT5 Cervical squamous cell carcinoma
35 202452 5 8200000 15100000 Gain DAP Cervical squamous cell carcinoma
36 202454 5 8200000 15100000 Gain MARCHF6 Cervical squamous cell carcinoma
37 202462 5 8200000 23300000 Gain ZFYVE16 Cervical squamous cell carcinoma
38 202464 5 8200000 45800000 Gain TTC33 Cervical squamous cell carcinoma

Expression for Cervical Squamous Cell Carcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Cervical Squamous Cell Carcinoma patients vs. healthy controls: 35 (show all 33)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CRNN cornulin Uterus - 5.62 0.000
2 KRT1 keratin 1 Uterus - 5.32 0.000
3 UPK1A uroplakin 1A Uterus - 4.79 0.000
4 MAL mal, T cell differentiation protein Uterus - 4.73 0.000
5 KRT4 keratin 4 Uterus - 4.45 0.000
6 SPRR3 small proline rich protein 3 Uterus - 4.43 0.000
7 DSG1 desmoglein 1 Uterus - 4.27 0.000
8 CDKN2A cyclin dependent kinase inhibitor 2A Uterus + 4.21 0.000
9 CRISP3 cysteine rich secretory protein 3 Uterus - 4.13 0.000
10 CRCT1 cysteine rich C-terminal 1 Uterus - 3.92 0.000
11 SPINK5 serine peptidase inhibitor Kazal type 5 Uterus - 3.67 0.000
12 SLURP1 secreted LY6/PLAUR domain containing 1 Uterus - 3.54 0.000
13 APOC1 apolipoprotein C1 Uterus + 3.53 0.000
14 HOPX HOP homeobox Uterus - 3.51 0.000
15 EDN3 endothelin 3 Uterus - 3.48 0.000
16 FANCI FA complementation group I Uterus + 3.42 0.000
17 SYNGR3 synaptogyrin 3 Uterus + 3.41 0.000
18 CRYAB crystallin alpha B Uterus - 3.39 0.000
19 KRT13 keratin 13 Uterus - 3.35 0.004
20 MCM5 minichromosome maintenance complex component 5 Uterus + 3.31 0.000
21 ALOX12 arachidonate 12-lipoxygenase, 12S type Uterus - 3.26 0.000
22 PPP1R3C protein phosphatase 1 regulatory subunit 3C Uterus - 3.23 0.000
23 SCEL sciellin Uterus - 3.19 0.000
24 NTS neurotensin Uterus + 3.19 0.006
25 NUSAP1 nucleolar and spindle associated protein 1 Uterus + 3.17 0.000
26 IVL involucrin Uterus - 3.14 0.000
27 IL1R2 interleukin 1 receptor type 2 Uterus - 3.14 0.000
28 CFD complement factor D Uterus - 3.13 0.000
29 SOSTDC1 sclerostin domain containing 1 Uterus - 3.08 0.000
30 ESR1 estrogen receptor 1 Uterus - 3.06 0.000
31 PAMR1 peptidase domain containing associated with muscle regeneration 1 Uterus - 3.06 0.000
32 ENDOU endonuclease, poly(U) specific Uterus - 3.04 0.000
33 HOXC6 homeobox C6 Uterus + 3.01 0.000
Search GEO for disease gene expression data for Cervical Squamous Cell Carcinoma.

Pathways for Cervical Squamous Cell Carcinoma

Pathways related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.36 SKP2 RASSF1 MLH1 KRAS DAPK1 CDKN2A
2 12.13 TP63 SKP2 MLH1 MKI67 CDKN2A
3 11.92 TP63 RASSF1 MIR29A MIR200A KRAS CDKN2A
4 10.88 TYMP RASSF1 KRAS DAPK1 CDKN2A

GO Terms for Cervical Squamous Cell Carcinoma

Biological processes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.55 TP63 RASSF1 MLH1 MKI67 CDKN2A
2 positive regulation of cellular senescence GO:2000774 8.96 KRAS CDKN2A
3 Ras protein signal transduction GO:0007265 8.8 RASSF1 KRAS CDKN2A

Molecular functions related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MDM2/MDM4 family protein binding GO:0097371 8.62 TP63 CDKN2A

Sources for Cervical Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....